• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2010 Fiscal Year Final Research Report

Basic analysis of anti-allergic agent MMKY-01, which accelerating drug sensitivity to gemicitabine in pancreatic cancer cell.

Research Project

  • PDF
Project/Area Number 20591632
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionSaga University

Principal Investigator

KITAJIMA Yoshihiko  Saga University, 医学部, 客員研究員 (30234256)

Project Period (FY) 2008 – 2010
Keywords膵癌 / 胆嚢癌 / ジェムシタビン / MMKY-01 / RRM1 / ユビキチン / TGF-β
Research Abstract

The present study demonstrated that MMKY-01 accelerates drug sensitivity to gemcitabine via decreasing RRM1 expression in pancreatic and gall bladder (GB) cancer cells. The reduced RRM1 expression was derived through ubiquitin-proteosome pathway in pancreatic cancer. Further analysis revealed that MMKY-01 rendered gemcitabine resistant GB cancer cell to apoptosis. These results indicated that MMKY-01 plus gemcitabine is possibly effective to pancreatic as well as GB cancer. Especially, MMKY-01 treatment was revealed to reverse the gemcitabine resistance in GB cancer.

  • Research Products

    (9 results)

All 2010 2009 2008 Other

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (6 results) Remarks (1 results)

  • [Journal Article] Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.2010

    • Author(s)
      Mayumi Mitsuno, Yoshihiko Kitajima, Kazuma Ohtaka, Keita Kai, Kazuyoshi Hashiguchi, Jun Nakamura, Masatsugu Hiraki, Hirokazu Noshiro, Kohji Miyazaki.
    • Journal Title

      Int J Oncol 36

      Pages: 341-349

    • Peer Reviewed
  • [Journal Article] Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistory predicts the efficacy of gemcitabine in biliary tract carcinoma.2010

    • Author(s)
      Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y, Tokunaga O, Noshiro H, Miyazaki K.
    • Journal Title

      Int J Oncol 37

      Pages: 845-852

    • Peer Reviewed
  • [Presentation] Gemcitabine耐性胆道癌細胞株におけるTranilastのApoptosis誘導作用の検討2009

    • Author(s)
      橋口和義、北島吉彦、平木将紹、中村淳、能城浩和、宮崎耕治
    • Organizer
      第20回日本消化器癌発生学会総会
    • Place of Presentation
      オリエンタルホテル広島
    • Year and Date
      20091126-20091127
  • [Presentation] Gemcitabine耐性胆道癌細胞株におけるTranilastのApoptosis誘導機構についての検討2009

    • Author(s)
      橋口和義、北島吉彦、平木将紹、中村淳、光野真由美、宮崎耕治
    • Organizer
      第68回日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜
    • Year and Date
      20091001-20091003
  • [Presentation] 膵癌におけるTranilastのRRM1発現抑制効果に基づいたTranilast+Gemcitabine(dFdC)併用療法の可能性2008

    • Author(s)
      北島吉彦、光野真由美、橋口和義、中村淳、平木将紹、大塚隆生、神谷尚彦、宮崎耕治
    • Organizer
      第19回日本消化器癌発生学会
    • Place of Presentation
      別府亀の井ホテル
    • Year and Date
      20080828-20080829
  • [Presentation] 胆道癌細胞株におけるTranilastのRRM1発現抑制効果を介したGemcitabine感受性増強作用2008

    • Author(s)
      橋口和義、光野真由美、北島吉彦、大高和真、平木将紹、中村淳、神谷尚彦、中房祐司、宮崎耕治
    • Organizer
      第108回日本外科学会定期学術集会
    • Place of Presentation
      長崎ブリックホール
    • Year and Date
      20080515-20080517
  • [Presentation] 膵癌に対するRRM1を分子標的としたTranilast+Gemcitabine併用療法の可能性2008

    • Author(s)
      光野真由美、北島吉彦、平木将紹、橋口和義、中村淳、神谷尚彦、宮崎耕治
    • Organizer
      第108回日本外科学会定期学術集会
    • Place of Presentation
      長崎ブリックホール
    • Year and Date
      20080515-20080517
  • [Presentation] Tranilast increased the drug effect of gemcitabine via protain degradation of RRM1 in pancreatic cancer cells.2008

    • Author(s)
      Yoshihiko Kitajima, Mayumi Mitsuno, Kazuyoshi Hashiguchi, Jun Nakamnura, Masatsugu Hiraki, Kohji Miyazaki
    • Organizer
      AACR annual meeting 2008
    • Place of Presentation
      San Diego, USA
    • Year and Date
      20080412-20080416
  • [Remarks] ホームページ等

URL: 

Published: 2012-01-26   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi